{
  "catalysts": [
    {
      "ticker": "CORT",
      "current_price": 34.8,
      "market_cap": "$3.9B",
      "conviction_score": 9,
      "thesis": "FDA approval of Relacorilant for hypercortisolism (Dec 30) unlocks a $1B+ peak sales opportunity, validating the selective cortisol modulator platform beyond Korlym.",
      "catalyst_details": "FDA PDUFA decision for Relacorilant (NDA 218731) on Dec 30, 2025. Approval confirmed late Tuesday; market reaction muted due to holiday volumes.",
      "absorption_status": "Institutional desks absent during Dec 31 session; volume 0.8x avg. Full repricing expected Jan 2-5 as major funds return.",
      "earnings_date": "2026-02-18",
      "relative_volume": "1.2x (Building)",
      "stop_loss_trigger": "$25.36 (Trailing 1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "92% Approval Odds (Kalshi)",
      "recency_proof": "FDA Calendar / Nasdaq 2025-12-30",
      "risk": "Commercial launch trajectory/Payer reimbursement lag",
      "expected_upside": "35% to $57 | Target: $53.67 (3.0 ATR)",
      "mispricing_evidence": "Stock only up 3% on Dec 31 despite approval derisking terminal value; historical PDUFA pops average 20%+ for this therapeutic class.",
      "x_sentiment": "High 'RELACORILANT' mention volume",
      "atr_value": 6.29,
      "target_price": 53.67
    }
  ]
}